Mecure Industries Plc delivered a sharp rebound in profitability for the year ended 31 December 2025, with profit after tax rising 177 per cent to N6.46 bn compared to N2.33 bn, according to its audited financial statements.

Revenue for the pharmaceutical manufacturer grew to N77.69bn in 2025, up from N46.03bn in 2024, representing a 69 per cent increase year-on-year. The growth in turnover was supported by improved sales performance across its product lines during the period.

The company recorded strong revenue growth across all product categories in 2025 compared with 2024, underscoring broad-based expansion in its portfolio. Revenue from the acute segment rose significantly to N42.57bn in 2025, up from N25.22bn in 2024, remaining the largest contributor to total turnover. The OTC category also delivered robust growth, increasing to N17.31bn from N10.26bn in the prior year.

Sales from supplements climbed to N8.70bn, compared with N5.15bn in 2024, while revenue generated from chronic products grew to N5.35bn from N3.17bn.

The Narcotics segment recorded N2.52bn in revenue, up from N1.49bn a year earlier. Promotional sales likewise increased to N1.24bn compared with N736.85m in 2024.

On the balance sheet, total assets rose to N81.96bn as of 31 December 2025, up from N54.84bn in 2024.

The Directors recommend a dividend payout of 20 per cent of Earnings Per Share, amounting to N0.32 per share, in respect of the financial performance for the year ended 31 December 2025, subject to the approval of the shareholders (2024: N0.15 per share).

The audited results point to a year of stronger operational execution and margin expansion for Mecure Industries, with revenue growth and cost discipline combining to deliver a marked improvement in profitability and shareholder returns.